Opto Circuits (India) Ltd., a manufacturer of healthcare devices said, the company's wholly owned subsidiary EuroCor Life Sciences has launched DIOR, a pioneering paclitaxel-eluting balloon dilation catheter used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Providing more details about the product the company said, DIOR is the first of its kind in the market that is used as life saving catheter. It can be effectively used in the treatment of coronary in-stent restenosis and treatment of small-diameter (less than 2.5mm) coronary artery lesions, which make for 4 per cent of the total market requirements.
EuroCor is the only company in the world to have obtained Conformité Européen (EC) certification for its drug eluting balloon catheters, a company press release said. With the CE accreditation in place, EuroCor is well poised for a massive market share in this product category, the press release noted.
The company pointed out that the world figure for stent implants stand at about 4 million. Out of this, 70 per cent constitutes drug eluting stents and the rest bare metal stents. The restenosis rates are 10 per cent and 30 per cent on drug eluting and bare metal stents, respectively. Given the state of affairs, the company said EuroCor expects 8, 56, 000 balloon catheters to be used on these patients, resulting in a revenue of US$1.20 billion.
Usually, Re-stenosis is treated with placing a stent within the existing stent. Some times it may result in higher re-stenosis. However, the application of DIOR will enable more significant result. DIOR enables the cardiologist to treat in-stent re-stenosis without placing another stent into the stent, ensuring the safety of patients for further interventions, the press release said.